Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sohini Mondal

MYSTERIOUS: Biogen stock is wall street bullish or bearish - You Need To See This

With a market cap of $24.6 billion, Biogen Inc. (BIIB) is a global biotechnology leader specializing in therapies for neurological and neurodegenerative diseases. Its portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Avonex, Plegridy, and Tysabri, as well as Spinraza for spinal muscular atrophy and several biosimilars. 

Shares of the Cambridge, Massachusetts-based company have underperformed the broader market over the past 52 weeks. BIIB stock has risen 1.6% over this time frame, while the broader S&P 500 Index ($SPX) has gained 13.2%. Moreover, shares of the company have returned 9.6% on a YTD basis, compared to SPX's 14.5% increase.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.